Six-sigma and quality planning of TORCH tests in the Peruvian population: a single-center cross-sectional study

BMC Res Notes. 2022 Jan 11;15(1):16. doi: 10.1186/s13104-022-05904-9.

Abstract

Objective: To ensure the health of newborns, it is necessary to perform high-quality diagnostic tests. The TORCH panel is a set of tests that identifies infectious pathogens such as Toxoplasma (Toxo) and Cytomegalovirus (CMV) that are common in low-setting populations. We performed TORCH panel quality planning using six sigma in a reference laboratory at Peru.

Results: This was a cross-sectional study. TORCH tests include Toxo, Rubella, CMV, and Herpes. We processed all samples by fourth-generation ELISA on the GEMINI XCR200 analyzer (Diatron, Budapest, Hungary). We obtained the imprecision from the annual data of the external quality assessment plan and we used the CLSI EP12-A3 guideline. In a total of 44,788 analyses, the average imprecision was 3.69 ± 1.47%, and CMV had lower imprecision (2.3 and 2.6% for IgM and IgG, respectively). Quality planning of the TORCH panel allowed estimating the sigma value that ranged from 4 to 10 (average 7 ± 2 sigma), where rubella had the highest values (10 for IgM and 8 for IgG) while HSV2 had the lowest values (4 for IgM and 5 for IgG). Our results suggest the optimal performance of half of the markers including Toxoplasma, Rubella, and CMV in the Peruvian population.

Keywords: Cytomegalovirus; Enzyme-linked immunosorbent assay; Quality assurance; Quality management; Six sigma; Toxoplasma.

MeSH terms

  • Cross-Sectional Studies
  • Female
  • Humans
  • Immunoglobulin M
  • Infant, Newborn
  • Peru
  • Pregnancy
  • Pregnancy Complications, Infectious*
  • Rubella* / diagnosis
  • Total Quality Management
  • Toxoplasma*
  • Toxoplasmosis*

Substances

  • Immunoglobulin M